Diclofenac potassium liquid-filled soft gelatin capsules for the treatment of postbunionectomy pain

被引:25
作者
Daniels, Stephen E. [1 ]
Baum, Douglas R. [2 ]
Clark, Francis [3 ]
Golf, Michael H.
McDonnell, Mark E. [4 ]
Boesing, Stephen E. [5 ]
机构
[1] Premier Res Grp Ltd, Clin Res Ctr, Austin, TX 78666 USA
[2] Pain Treatment Dev Inc, Austin, TX USA
[3] Foot & Ankle Inst, W Jordan, UT USA
[4] Hill Country Sports Med, Austin, TX USA
[5] Xanodyne Pharmaceut Inc, Newport, KY USA
关键词
Bunionectomy; Diclofenac potassium; Dispersion technology; Pain relief; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HEALTHY-VOLUNTEERS; COMPARATIVE BIOAVAILABILITY; ANALGESIC EFFICACY; BUNIONECTOMY PAIN; DENTAL PAIN; SURGERY; FORMULATIONS; VALDECOXIB; ROFECOXIB;
D O I
10.1185/03007995.2010.515478
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Diclofenac potassium liquid-filled soft gelatin capsule (DPSGC) is a rapidly absorbed formulation of diclofenac approved for the treatment of mild to moderate acute pain in adults (>= 18 years of age). The objective of this study was to investigate the efficacy and safety of DPSGC 25 mg in a multicenter, randomized, double-blind, placebo-controlled study in patients experiencing pain following first metatarsal bunionectomy. Research design and methods: Patients experiencing a requisite level of pain (>= 4 based on an 11-point numeric pain rating scale [NPRS]; 0 = no pain, 10 = worst pain possible) on the day following surgery were randomized to receive DPSGC 25 mg or placebo. Patients received a second dose (remedication) on request or at 8 hours postdose followed by additional doses every 6 hours through the end of postsurgery Day 4. Rescue medication (hydrocodone/acetaminophen) was available as needed after the second dose. Clinical trial registration: NCT00375934. Main outcome measure: The primary efficacy endpoint was the average NPRS score over the 48 hour inpatient multiple-dose period. Results: DPSGC provided a significant improvement in mean 48 hour NPRS scores over placebo (3.29 vs 5.74, respectively; p<0.0001), as well as for summed pain intensity difference (203.1 vs 86.6; p<0.0001). Patients treated with DPSGC experienced a faster onset of meaningful pain relief compared with placebo (p=0.0034). Rescue medication use on Day 1 and Day 2 was reduced in the DPSGC group compared with placebo (53.5% vs 92.1% on Day 1; 30.3% vs 67.3% on Day 2; p<0.0001). DPSGC was well tolerated and no patients treated with DPSGC reported serious adverse events. As with any study, there are potential limitations including study design and patient population. Conclusion: These results indicate that DPSGC reduced pain in patients who underwent bunionectomy and this novel formulation of diclofenac potassium may be a practical option for treating mild to moderate acute pain.
引用
收藏
页码:2375 / 2384
页数:10
相关论文
共 24 条
[21]  
Van Hecken A, 2000, J CLIN PHARMACOL, V40, P1109
[22]   Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs [J].
Wolfe, MM ;
Lichtenstein, DR ;
Singh, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (24) :1888-1899
[23]  
Worrell J B, 1996, AANA J, V64, P146
[24]   Analgesic safety and efficacy of diclofenac sodium softgels on postoperative third molar extraction pain [J].
Zuniga, JR ;
Phillips, CL ;
Shugars, D ;
Lyon, JA ;
Peroutka, SJ ;
Swarbrick, J ;
Bon, C .
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2004, 62 (07) :806-815